Trial · NCT07136792
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792, Not applicable, Recruiting, Guangdong Provincial People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI). Trials, record NCT07136792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07136792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
- NCT number
- NCT07136792
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 96 participants, estimated
- Lead sponsor
- Guangdong Provincial People's Hospital
- Conditions
- Renal Anemia of Chronic Kidney Disease
- Interventions
- Pegmolesatide 2mg SC, Pegmolesatide 4mg SC, Pegmolesatide 4mg SC, Pegmolesatide 6mg SC
- First posted
- 2025-08-22
- Last updated
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of mean HB level | from baseline to 12 weeks and 16 weeks | Change of mean HB level from baseline to 12 weeks and 16 weeks |
| Secondary | Change of mean HB level | from baseline to 12 weeks and 16 weeks | Change in mean HB levels from baseline to 12 weeks and 16 weeks, stratified by different baseline HB levels |
| Secondary | Changes in red blood cell count | from baseline to 4 weeks, 8 weeks, 12 weeks, 16 weeks | Changes in red blood cell count from baseline to each follow-up |
| Secondary | Median time to the first HB value reaching 10.0-12.0 g/dl | From baseline to 4 weeks, 8 weeks,12 weeks and 16 weeks | Median time to the first HB value reaching 10.0-12.0 g/dl |
| Secondary | Proportion of patients with HB 10.0-12.0 g/dl | from baseline to 4 weeks, 8 weeks,12 weeks and 16 weeks | Proportion of patients with HB 10.0-12.0 g/dl at each follow-up |
| Secondary | Proportion of patients with HB 11.0-13.0 g/dl | from baseline to 4 weeks, 8 weeks, 12 weeks and 16 weeks | Proportion of patients with HB11.0-13.0 g/dl at each follow-up |
| Secondary | Average drug dose at each follow-up | From baseline to 4 weeks, 8 weeks,12 weeks and 16 weeks | |
| Secondary | Adverse Events | From the start of study drug to 30 days after the last dose of study drug | Safety of therapy by Investigator. |
| Other | The Maximum Plasma Concentration | from the start of study drug to to 48 hours, 72 hours and 96 hours | The Maximum Plasma Concentration of Pegmolesatide |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07136792
GET https://conductscience.org/api/trials/v1/NCT07136792/registered